Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gilead Complera Launch Imminent Following FDA Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

Antiretroviral combines Gilead's Truvada with J&J's Edurant for HIV, and is intended as a replacement to the existing triple combination Atripla.
Advertisement

Related Content

Deal Watch: Gilead’s Move Into NASH Highlights Post-Holiday Deal-Making
Gilead Already Seeking Stribild Successor, Going Solo On Key HCV Combo
Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
Gilead Clarifies Quad Will Come First, Over Detailing For Triple Combo Complera
Optimer's Fidaxomicin Among Three NMEs Given Positive Review By Europe's Regulators
On A Roll: Gilead's Top-Line Quad Data Stack Up To Atripla
Firm Finds Novel Mechanism Of Action For HIV A Hard Sell For Investors
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Rilpivirine Label Highlights Risk In Patients With Higher HIV Levels, Could Limit Use
Gilead Recruits Hepatitis C Specialist McHutchison In Show Of Commitment

Topics

Advertisement
UsernamePublicRestriction

Register

PS072629

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel